UCSF Helen Diller Family Comprehensive Cancer Center

Co-discovered that BRCA-deficient cancers die when PARP is blocked, the idea behind an entire drug class.

GI oncologist who led CALGB/SWOG 80405 and helped show that tumour side matters in colorectal cancer.

Neuroendocrine tumour specialist who helps design the trials that set treatment for these rare cancers.

Prostate cancer trialist who helped bring abiraterone and sipuleucel-T to patients, and led ASCO in 2025-26.

RAS biologist who founded Onyx Pharmaceuticals and led the NCI's national effort to drug RAS.

Paediatric oncologist whose trials established transplant and 13-cis-retinoic acid for high-risk neuroblastoma.

The chemist whose lab found the hidden pocket in KRAS G12C that made the 'undruggable' target druggable.

Breast surgeon who built the I-SPY platform, the adaptive trial that tests new drugs before surgery.

Prostate oncologist studying how tumours transform to escape hormone therapy and how to target them with radioligands.

Nuclear medicine physician who led the trials that got PSMA PET approved in the United States.